1334719-95-7 Usage
Description
Q203, also known as TMC-207, is a potent and selective inhibitor of the mycobacterial respiratory cytochrome bc1 complex, which is essential for the growth and survival of Mycobacterium tuberculosis, the bacteria that causes tuberculosis. It possesses strong anti-tubercular activity and has the potential to overcome resistance to existing drugs.
Uses
Used in Pharmaceutical Industry:
Q203 is used as an anti-tubercular agent for its ability to inhibit the growth of both drug-sensitive and drug-resistant strains of M. tuberculosis. It demonstrates synergistic effects when combined with other anti-tubercular agents, enhancing the overall efficacy of treatment.
Used in Clinical Trials:
Q203 is used in clinical trials to investigate its potential as a treatment for drug-resistant tuberculosis. The promising results from these trials highlight its potential as a novel and effective anti-tubercular agent capable of addressing the growing problem of drug resistance in tuberculosis treatment.
Check Digit Verification of cas no
The CAS Registry Mumber 1334719-95-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,3,4,7,1 and 9 respectively; the second part has 2 digits, 9 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1334719-95:
(9*1)+(8*3)+(7*3)+(6*4)+(5*7)+(4*1)+(3*9)+(2*9)+(1*5)=167
167 % 10 = 7
So 1334719-95-7 is a valid CAS Registry Number.
1334719-95-7Relevant articles and documents
Cobalt-Catalyzed Electrophilic Amination of Aryl- and Heteroarylzinc Pivalates with N-Hydroxylamine Benzoates
Chen, Yi-Hung,Gra?l, Simon,Knochel, Paul
, p. 1108 - 1111 (2018/01/01)
Aryl- and heteroarylzinc pivalates can be aminated with O-benzoylhydroxylamines at 25 °C within 2–4 h in the presence of 2.5–5.0 % CoCl2?2 LiCl to furnish the corresponding tertiary arylated or heteroarylated amines in good yields. This electrophilic amination also provides access to diarylamines and aryl(heteroaryl)amines. A new tuberculosis drug candidate (Q203) was prepared in six steps and 56 % overall yield by using this cobalt-catalyzed amination as the key step.
ANTI-INFECTIVE COMPOUNDS
-
Page/Page column 126, (2011/10/10)
The present invention relates to small molecule compounds and their use in the treatment of bacterial infections, in particular Tuberculosis.
